Calamos Advisors’s Psyence Biomedical Warrant PBMWW Stock Holding History

Calamos Advisors’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5K	Hold	500,000	–	–	﹤0.01%	958
2026 Q1	$9.05K	Hold	500,000	–	–	﹤0.01%	1175
2025 Q4	$9.85K	Hold	500,000	–	–	﹤0.01%	897
2025 Q3	$12.5K	Hold	500,000	–	–	﹤0.01%	890
2025 Q2	$10.1K	Hold	500,000	–	–	﹤0.01%	884
2025 Q1	$8.45K	Hold	500,000	–	–	﹤0.01%	873
2024 Q4	$6.15K	Hold	500,000	–	–	﹤0.01%	877
2024 Q3	$6.35K	Hold	500,000	–	–	﹤0.01%	895
2024 Q2	$5.3K	Hold	500,000	–	–	﹤0.01%	907
2024 Q1	$35.8K	Buy	+500,000	New	+$31.1K	﹤0.01%	832

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Calamos Advisors's PBMWW Position: Q2 2026 in Review

Calamos Advisors held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 500,000 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #958.

Calamos Advisors first reported a position in PBMWW in Q1 2024 and has held it in 10 quarters since. The position peaked at $35.8K in Q1 2024. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

Calamos Advisors held 500,000 shares of Psyence Biomedical Warrant worth $10.5K as of Q2 2026.
Calamos Advisors left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #958 holding.
Calamos Advisors first reported a position in Psyence Biomedical Warrant in Q1 2024 and has held it in 10 quarters since.
Calamos Advisors's Psyence Biomedical Warrant position peaked at $35.8K in Q1 2024.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.